Atazanavir/ritonavir monotherapy — Competitive Intelligence Brief

Atazanavir/ritonavir monotherapy (Atazanavir/ritonavir monotherapy) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: HIV protease inhibitor. Area: Infectious Disease.

phase 3 HIV protease inhibitor HIV protease Infectious Disease Small molecule

Target snapshot

Atazanavir/ritonavir monotherapy (Atazanavir/ritonavir monotherapy) — IRCCS San Raffaele. Atazanavir/ritonavir inhibits HIV protease to prevent viral replication, with ritonavir boosting atazanavir levels through CYP3A4 inhibition.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Atazanavir/ritonavir monotherapy TARGET	Atazanavir/ritonavir monotherapy	IRCCS San Raffaele	phase 3	HIV protease inhibitor	HIV protease
Raltegravir and Atazanavir	Raltegravir and Atazanavir	Peter J. Ruane, M.D., Inc.	marketed	Antiretroviral combination (integrase inhibitor + protease inhibitor)	HIV integrase and HIV protease
Reducing dose of Lopinavir	Reducing dose of Lopinavir	University Hospital, Geneva	marketed	HIV protease inhibitor	HIV protease
Switch ritonavir-boosted PI	Switch ritonavir-boosted PI	Juan A. Arnaiz	marketed	Protease inhibitor (boosted)	HIV protease
TAF with a boosted protease inhibitor	TAF with a boosted protease inhibitor	University of Colorado, Denver	marketed	Antiretroviral combination (nucleotide reverse transcriptase inhibitor + protease inhibitor)	HIV reverse transcriptase and HIV protease
Lopinavir/ritonavir 4:1	Lopinavir/ritonavir 4:1	Drugs for Neglected Diseases	marketed	HIV protease inhibitor	HIV protease
Raltegravir, lopinavir, ritonavir	Raltegravir, lopinavir, ritonavir	Allina Health System	marketed	Antiretroviral combination therapy (integrase inhibitor + protease inhibitors)	HIV integrase, HIV protease

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (HIV protease inhibitor class)

1. Bristol-Myers Squibb · 5 drugs in this class
2. ViiV Healthcare · 3 drugs in this class
3. GlaxoSmithKline · 2 drugs in this class
4. Drugs for Neglected Diseases · 2 drugs in this class
5. Germans Trias i Pujol Hospital · 2 drugs in this class
6. Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · 1 drug in this class
7. DualityBio Inc. · 1 drug in this class
8. French National Agency for Research on AIDS and Viral Hepatitis · 1 drug in this class
9. Far East Bio-Tec Co., Ltd · 1 drug in this class
10. Community Research Initiative of New England · 1 drug in this class